Tocris Bioscience 社 エピジェネティクスを標的とした化合物
エピジェネティクスとは、DNA 配列の変化を伴わずにクロマチン構造が変化することで、遺伝子発現が制御される現象です。ヒストンのアセチル化・メチル化、DNA のメチル化、ユビキチン化などの修飾が関与し、がんの発症や進行に深く関わっています。Tocris Bioscience 社（以下 Tocris 社）では、エピジェネティクス研究に役立つ化合物を取りそろえています。
Tocris 社が「がんエピジェネティクス（Epigenetics in Cancer）」冊子を用意していますので、ぜひご覧ください。
※国内法規・特許により、一部弊社で取り扱いできない化合物がございます。
製品説明
ターゲット
がん研究におけるエピジェネティクスを標的とした約 120 種類の化合物を紹介しています。
ヒストンのメチル化
- Histone Methyltransferases
- Histone Demethylases
ヒストンのアセチル化
- Histone Acetyltransferases
- Histone Deacetylases
ブロモドメイン
ユビキチン化
- Histone Ubiquitinating Enzymes
- Histone Deubiquitinating Enzymes
DNA のメチル化
ポリ ADP-リボシル化酵素
関連資料
Tocris 社では、がん研究をサポートするため、特定分野の冊子を用意しています！
価格表
各製品の容量は、オンラインカタログでご確認いただけます。
| カテゴリー | 製品名 | 作用 | メーカー 製品番号 |
オンライン カタログへ |
|---|---|---|---|---|
| Bromodomains (BRDs) | AZ 13824374 | Potent and selective ATAD2 bromodomain inhibitor | 7757 |  |
| BAY 299 | Potent and selective BRD1 and TAF1 inhibitor | 5970 | |
|
| BAZ2‑ICR | Selective BAZ2 inhibitor | 5266 | |
|
| BI 9564 | Potent and selective BRD9 and BRD7 inhibitor; orally bioavailable | 5590 | |
|
| CeMMEC1 | TAF1 inhibitor | 7139 | |
|
| CPI 203 | BET bromodomain inhibitor; arrests cell cycle at G1 phase | 5331 | |
|
| FHT 1015 | Potent and selective SMARCA4/2 inhibitor | 7644 | |
|
| FHT 2344 | Potent SMARCA2/4 inhibitor | 7645 | |
|
| GSK 6853 | Potent and selective BRPF1 inhibitor | 6198 | |
|
| I‑BET 151 | BET bromodomain inhibitor; also promotes differentiation of hiPSCs into megakaryocytes | 4650 | |
|
| I‑BET 762 | Potent and high affinity BET bromodomain inhibitor; anti‑inflammatory; orally bioavailable | 6521 | |
|
| iBET‑BD2 | Potent and selective pan‑BD2 inhibitor; orally bioavailable | 7458 | |
|
| I‑BRD9 | Potent and selective BRD9 inhibitor | 5591 | |
|
| (+)‑JQ1 | Potent and selective BET bromodomain inhibitor; cell permeable | 4499 | |
|
| NVS MLLT‑1 | Selective MLLT1/3 inhibitor | 7482 | |
|
| PFI 3 | Potent and selective SMARCA2/4 and polybromo 1 inhibitor | 5072 | |
|
| Rapamycin | mTOR inhibitor; immunosuppressant | 1292 | |
|
| SGC SMARCA‑BRDVIII | Potent and selective SMARCA2/4 and PB1(bromo 5)‑selective SWI/SNF bromodomain inhibitor | 7460 | |
|
| TP 238 | CECR2 and BPTF/FALZ inhibitor | 6670 | |
|
| TP 472 | Potent BRD9/7 inhibitor | 6000 | |
|
| Deubiquitination | Spautin 1 | USP10 and USP13 inhibitor; inhibits autophagy | 5197 | |
| DNA Methyltransferases (DNMTs) | 5‑Azacytidine | DNA methyltransferase inhibitor | 3842 | |
| EGCG | β‑secretase (BACE) inhibitor; inhibits amyloid assembly | 4524 | |
|
| Fisetin | Naturally occurring flavonoid and antioxidant; neuroprotective | 5016 | |
|
| Lomeguatrib | MGMT inhibitor | 4359 | |
|
| RG 108 | Non‑nucleoside DNA methyltransferase inhibitor | 3295 | |
|
| Zebularine | DNA methyltransferase and cytidine deaminase inhibitor | 2293 | |
|
| 6‑Thioguanine | Anticancer and immunosuppressive agent | 4061 | |
|
| Histone Acetyltransferases (HATs) | A485 | Potent and selective p300/CBP inhibitor; orally bioavailable | 6387 | |
| iP300w | Potent p300/CBP inhibitor | 7270 | |
|
| NU 9056 | Inhibitor of KAT5 (Tip60) | 4903 | |
|
| WM 8014 | Potent and selective KAT6A and KAT6B inhibitor | 6693 | |
|
| WM 3835 | Lysine acetyltransferase HBO1 (KAT7) inhibitor | 7366 | |
|
| Histone Deacetylases (HDACs) | EX 527 | Selective SIRT1 inhibitor | 2780 | |
| MC 1568 | Selective HDAC class IIa inhibitor | 4077 | |
|
| MS 275 | HDAC (Class I) inhibitor | 6208 | |
|
| Panobinostat | Pan‑histone deacetylase inhibitor | 7629 | |
|
| PCI 34051 | Potent and selective HDAC8 inhibitor | 4643 | |
|
| RGFP 966 | Potent and selective HDAC3 inhibitor | 6728 | |
|
| SAHA | Class I and II HDAC inhibitor | 4652 | |
|
| Santacruzamate A | Highly potent and selective HDAC2 inhibitor | 7191 | |
|
| Sodium butyrate | Histone deacetylase inhibitor | 3850 | |
|
| Sodium 4‑Phenylbutyrate | Histone deacetylase inhibitor | 2682 | |
|
| Trichostatin A | Potent histone deacetylase inhibitor | 1406 | |
|
| Tubacin | HDAC6 inhibitor; inhibits α‑tubulin deacetylation | 3402 | |
|
| Valproic acid | Histone deacetylase inhibitor | 2815 | |
|
| Histone Demethylases (KDMs) | GSK J1 | Potent JMJD3/UTX inhibitor | 4593 | |
| GSK J4 | Histone KDM inhibitor; cell permeable | 4594 | |
|
| IOX 1 | Histone demethylase inhibitor; cell permeable | 4464 | |
|
| JIB 04 | Pan Jumonji inhibitor; active in vivo | 4972 | |
|
| JQKD 82 | Selective inhibitor of lysine demethylase 5 | 7676 | |
|
| JTV 519 | Ryanodine receptor (RyR) inhibitor | 4564 | |
|
| NSC 636819 | KDM4A/KDM4B inhibitor | 5287 | |
|
| RN 1 | LSD1 inhibitor | 4977 | |
|
| TC‑E 5002 | Selective KDM2/7 inhibitor | 5089 | |
|
| GSK J2 | Inactive control of GSK J1 (Cat. No. 4593) | 4688 | |
| Lysine Methyltransferases (KMTs) | A 366 | Potent and selective G9a/GLP inhibitor | 5163 | |
| BAY 598 | Potent and selective SMYD2 inhibitor | 5991 | |
|
| Chaetocin | SUV39H1 inhibitor | 4504 | |
|
| EPZ 004777 | Highly potent DOT1L inhibitor | 5567 | |
|
| MM 102 | Potent WDR5/MLL interaction inhibitor | 5307 | |
|
| (R)‑PFI 2 | Potent and selective SETD7 inhibitor | 4892 | |
|
| SGC 0946 | Highly potent and selective DOT1L inhibitor; cell permeable | 4541 | |
|
| UNC 0224 | Potent G9a and GLP inhibitor | 3861 | |
|
| UNC 0638 | Selective G9a and GLP inhibitor | 4343 | |
|
| UNC 0642 | Potent and selective G9a and GLP inhibitor | 5132 | |
|
| UNC 1999 | Potent and selective EZH2/EZH1 inhibitor | 4904 | |
|
| OICR 9429 | High affinity and selective WDR5 antagonist | 5267 | |
|
| (S)‑PFI 2 | Negative control of (R)‑PFI 2 hydrochloride (Cat. No. 4892) | 5400 | |
|
| WDR5 0103 | WDR5 antagonist | 5323 | |
|
| Poly (ADP-ribose) Polymerases (PARPs) | AZD 2461 | Potent PARP inhibitor; orally bioavailable | 6060 | |
| EB 47 | Potent PARP‑1 inhibitor | 4140 | |
|
| GeA‑69 | Selective allosteric PARP14 inhibitor | 6795 | |
|
| Nicotinamide | PARP‑1 inhibitor | 4106 | |
|
| Olaparib | Potent PARP inhibitor | 7579 | |
|
| PJ 34 | Potent PARP inhibitor | 3255 | |
|
| Rucaparib camsylate | PARP inhibitor | 6230 | |
|
| Thalidomide | Binds cereblon; also TNF-α synthesis inhibitor | 0652 | |
|
| XAV 939 | Potent tankyrase inhibitor | 3748 | |
|
| WIKI4 | Potent tankyrase inhibitor | 4855 | |
|
| Polycomb Repressor Complex | A 366 | Potent and selective G9a/GLP inhibitor | 5163 | |
| EED 226 | Potent and selective EED inhibitor | 7762 | |
|
| UNC 0638 | Selective G9a and GLP inhibitor | 4343 | |
|
| UNC 0642 | Potent and selective G9a and GLP inhibitor | 5132 | |
|
| UNC 1999 | Potent and selective EZH2/EZH1 inhibitor | 4904 | |
|
| PROTAC® Degraders | dBRD9‑A | Potent BRD9 Degrader (PROTAC®) | 6943 | |
| JQAD1 | Potent and selective EP300 Degrader (PROTAC®) | 7682 | |
|
| MZ 1 | (+)‑JQ1 based Degrader (PROTAC®) that selectively degrades BRD4 | 6154 | |
|
| SK 575 | Potent PARP1 Degrader (PROTAC®) | 7583 | |
|
| VZ 185 | Potent and selective BRD7/9 Degrader (PROTAC®) | 6936 | |
|
| Protein Arginine Methyltransferases (PRMTs) | EPZ 015666 | Potent and selective PRMT5 inhibitor | 6516 | |
| SGC 6870 | Potent and selective PRMT6 allosteric inhibitor | 7182 | |
|
| TP 064 | Potent and selective PRMT4 inhibitor | 6008 | |
|
| Protein Ser/Thr Phosphatases | GSK 2830371 | Potent and selective allosteric inhibitor of Wip1 phosphatase | 5140 | |
| Okadaic acid | Protein phosphatase 1 and 2A inhibitor | 1136 | |
|
| Sanguinarine chloride | Inhibitor of protein phosphatase 2C (PP2C) | 2302 | |
|
| Protein Tyrosine Phosphatases | Alexidine dihydrochloride | Selective inhibitor of PTPMT1 | 3979 | |
| Sodium orthovanadate | Protein tyrosine phosphatase inhibitor | 2821 | |
|
| RNA/DNA Polymerase | Mithramycin A | Inhibitor of DNA and RNA polymerase | 1489 | |
| Triptolide | Inhibits RNAPII‑mediated transcription; antitumor, anti‑inflammatory and immunosuppressive | 3253 | |
|
| Ubiquitination | PRT 4165 | Inhibitor of Bmi1/Ring1A; blocks histone H2A ubiquitination | 5047 | |
| Rapamycin | mTOR inhibitor; immunosuppressant | 1292 | |
|
| SMER 3 | Selective inhibitor of E3 ubiquitin ligase | 4375 | |
|
| SZL P1‑41 | Selective Skp2 inhibitor; suppresses E3 ligase activity | 5076 | |
|
| Nutlin‑3 | MDM2 antagonist; inhibits MDM2‑p53 interaction | 3984 | |
|
| Nutlin 3a | MDM2 antagonist; active enantiomer of Nutlin‑3 (Cat. No. 3984) | 6075 | |
※掲載内容は 2025 年 9 月現在の情報に基づいています。